Spotlight on Dermatology

Credits: 1.25 CME
Expert Perspectives on Current and Emerging Therapies in Chronic Spontaneous Urticaria
Allen P. Kaplan, MD
Vindico Medical Education

Expert Perspectives on Current and Emerging Therapies in Chronic Spontaneous Urticaria

Start

Activity Details

Free CME
1.25 AMA PRA Category 1 Credit(s)
Released: September 22, 2022
Expires: September 21, 2023
75 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is allergists, dermatologists, allergy nurse practitioners, allergy physician assistants, dermatology nurse practitioners, dermatology physician assistants, and other health care professionals involved in the management of patients with chronic spontaneous urticaria.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Review the burden and impact of chronic spontaneous urticaria (CSU) on health-related quality of life.
  • Examine the role of biomarkers and their implications in CSU management.
  • Evaluate the current and emerging treatments for first, second, and subsequent lines of therapies in patients with CSU—including similarities and differences in the guideline recommendations by major consensus groups.

Activity Description

In this educational activity, expert clinicians will review the burden of CSU on health-related quality of life, the role of biomarkers in the management of CSU, the current treatment guidelines and their similarities and differences, and the clinical data supporting the available and emerging therapies for CSU.

Agenda

Chronic Spontaneous Urticaria: Burden, Clinical Implications of Biomarkers
Kristin Sokol, MD, MPH, MS

CSU Guidelines: Similarities and Differences
Allen P. Kaplan, MD

CSU Management: A Focus on Emerging Therapies
Thomas B. Casale, MD, FACP, FAAAAI, FACAAI

Activity Chair

Allen P. Kaplan, MD
Professor of Medicine
The Medical University of South Carolina
Charleston, SC

Disclosures
Advisor: Abb-RISA, AstraZeneca, Genetech, Novartis, Roche, Sanofi
Consultant: Celldex, Novartis

Faculty

Thomas B. Casale, MD, FACP, FAAAAI, FACAAI
Chief Medical Advisor Food Allergy Research and Education (FARE)
Distinguished Chair, FARE Clinical Network
Professor of Medicine and Pediatrics
Director, Division of Allergy and Immunology Joy McCann Culverhouse Clinical Research Center
University of South Florida
Tampa, FL

Disclosures
Consultant: Genentech, GlaxoSmithKline, Novartis, Sanofi-Regeneron
Speaker Contracted by Ineligible Company: Genentech, GlaxoSmithKline, Sanofi-Regeneron
Independent Research Contractor: Genentech, Sanofi-Regeneron
Data Safety Monitoring Board: Novartis

Kristin Sokol, MD, MPH, MS
Allergist/Immunologist Physician
Schreiber Allergy
Rockville, MD

Disclosures
Speaker Contracted by Ineligible Company: Regeneron/Sanofi

Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Relationship information is accurate at the time of content development.

Vindico Medical Education Staff:
No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.25 hours credit for completing this program.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Unlabeled and Investigational Usage

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.

Disclaimer Statement

The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Notice

Faculty, topics, program schedule, and credit hours are subject to change. Recording of any manner is prohibited without written permission from Vindico Medical Education, Office of Medical Affairs and Compliance.

Contact Information for Questions About the Activity

CME Questions?
Contact us at cme@vindicoCME.com

Activity Details

Free CME
1.25 AMA PRA Category 1 Credit(s)
Released: September 22, 2022
Expires: September 21, 2023
75 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is allergists, dermatologists, allergy nurse practitioners, allergy physician assistants, dermatology nurse practitioners, dermatology physician assistants, and other health care professionals involved in the management of patients with chronic spontaneous urticaria.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Review the burden and impact of chronic spontaneous urticaria (CSU) on health-related quality of life.
  • Examine the role of biomarkers and their implications in CSU management.
  • Evaluate the current and emerging treatments for first, second, and subsequent lines of therapies in patients with CSU—including similarities and differences in the guideline recommendations by major consensus groups.

Activity Description

In this educational activity, expert clinicians will review the burden of CSU on health-related quality of life, the role of biomarkers in the management of CSU, the current treatment guidelines and their similarities and differences, and the clinical data supporting the available and emerging therapies for CSU.

Agenda

Chronic Spontaneous Urticaria: Burden, Clinical Implications of Biomarkers
Kristin Sokol, MD, MPH, MS

CSU Guidelines: Similarities and Differences
Allen P. Kaplan, MD

CSU Management: A Focus on Emerging Therapies
Thomas B. Casale, MD, FACP, FAAAAI, FACAAI

Activity Chair

Allen P. Kaplan, MD
Professor of Medicine
The Medical University of South Carolina
Charleston, SC

Disclosures
Advisor: Abb-RISA, AstraZeneca, Genetech, Novartis, Roche, Sanofi
Consultant: Celldex, Novartis

Faculty

Thomas B. Casale, MD, FACP, FAAAAI, FACAAI
Chief Medical Advisor Food Allergy Research and Education (FARE)
Distinguished Chair, FARE Clinical Network
Professor of Medicine and Pediatrics
Director, Division of Allergy and Immunology Joy McCann Culverhouse Clinical Research Center
University of South Florida
Tampa, FL

Disclosures
Consultant: Genentech, GlaxoSmithKline, Novartis, Sanofi-Regeneron
Speaker Contracted by Ineligible Company: Genentech, GlaxoSmithKline, Sanofi-Regeneron
Independent Research Contractor: Genentech, Sanofi-Regeneron
Data Safety Monitoring Board: Novartis

Kristin Sokol, MD, MPH, MS
Allergist/Immunologist Physician
Schreiber Allergy
Rockville, MD

Disclosures
Speaker Contracted by Ineligible Company: Regeneron/Sanofi

Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Relationship information is accurate at the time of content development.

Vindico Medical Education Staff:
No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.25 hours credit for completing this program.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Unlabeled and Investigational Usage

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.

Disclaimer Statement

The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Notice

Faculty, topics, program schedule, and credit hours are subject to change. Recording of any manner is prohibited without written permission from Vindico Medical Education, Office of Medical Affairs and Compliance.

Contact Information for Questions About the Activity

CME Questions?
Contact us at cme@vindicoCME.com

Dermatology Presentations

1.25 CME
Vindico Medical Education
Expert Perspectives on Current and Emerging Therapies in Chronic Spontaneous Urticaria

Expert Perspectives on Current and Emerging Therapies in Chronic Spontaneous Urticaria

Start

Activity Details

Free CME
1.25 AMA PRA Category 1 Credit(s)
Released: September 22, 2022
Expires: September 21, 2023
75 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is allergists, dermatologists, allergy nurse practitioners, allergy physician assistants, dermatology nurse practitioners, dermatology physician assistants, and other health care professionals involved in the management of patients with chronic spontaneous urticaria.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Review the burden and impact of chronic spontaneous urticaria (CSU) on health-related quality of life.
  • Examine the role of biomarkers and their implications in CSU management.
  • Evaluate the current and emerging treatments for first, second, and subsequent lines of therapies in patients with CSU—including similarities and differences in the guideline recommendations by major consensus groups.

Activity Description

In this educational activity, expert clinicians will review the burden of CSU on health-related quality of life, the role of biomarkers in the management of CSU, the current treatment guidelines and their similarities and differences, and the clinical data supporting the available and emerging therapies for CSU.

Agenda

Chronic Spontaneous Urticaria: Burden, Clinical Implications of Biomarkers
Kristin Sokol, MD, MPH, MS

CSU Guidelines: Similarities and Differences
Allen P. Kaplan, MD

CSU Management: A Focus on Emerging Therapies
Thomas B. Casale, MD, FACP, FAAAAI, FACAAI

Activity Chair

Allen P. Kaplan, MD
Professor of Medicine
The Medical University of South Carolina
Charleston, SC

Disclosures
Advisor: Abb-RISA, AstraZeneca, Genetech, Novartis, Roche, Sanofi
Consultant: Celldex, Novartis

Faculty

Thomas B. Casale, MD, FACP, FAAAAI, FACAAI
Chief Medical Advisor Food Allergy Research and Education (FARE)
Distinguished Chair, FARE Clinical Network
Professor of Medicine and Pediatrics
Director, Division of Allergy and Immunology Joy McCann Culverhouse Clinical Research Center
University of South Florida
Tampa, FL

Disclosures
Consultant: Genentech, GlaxoSmithKline, Novartis, Sanofi-Regeneron
Speaker Contracted by Ineligible Company: Genentech, GlaxoSmithKline, Sanofi-Regeneron
Independent Research Contractor: Genentech, Sanofi-Regeneron
Data Safety Monitoring Board: Novartis

Kristin Sokol, MD, MPH, MS
Allergist/Immunologist Physician
Schreiber Allergy
Rockville, MD

Disclosures
Speaker Contracted by Ineligible Company: Regeneron/Sanofi

Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Relationship information is accurate at the time of content development.

Vindico Medical Education Staff:
No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.25 hours credit for completing this program.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Unlabeled and Investigational Usage

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.

Disclaimer Statement

The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Notice

Faculty, topics, program schedule, and credit hours are subject to change. Recording of any manner is prohibited without written permission from Vindico Medical Education, Office of Medical Affairs and Compliance.

Contact Information for Questions About the Activity

CME Questions?
Contact us at cme@vindicoCME.com

Activity Details

Free CME
1.25 AMA PRA Category 1 Credit(s)
Released: September 22, 2022
Expires: September 21, 2023
75 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is allergists, dermatologists, allergy nurse practitioners, allergy physician assistants, dermatology nurse practitioners, dermatology physician assistants, and other health care professionals involved in the management of patients with chronic spontaneous urticaria.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Review the burden and impact of chronic spontaneous urticaria (CSU) on health-related quality of life.
  • Examine the role of biomarkers and their implications in CSU management.
  • Evaluate the current and emerging treatments for first, second, and subsequent lines of therapies in patients with CSU—including similarities and differences in the guideline recommendations by major consensus groups.

Activity Description

In this educational activity, expert clinicians will review the burden of CSU on health-related quality of life, the role of biomarkers in the management of CSU, the current treatment guidelines and their similarities and differences, and the clinical data supporting the available and emerging therapies for CSU.

Agenda

Chronic Spontaneous Urticaria: Burden, Clinical Implications of Biomarkers
Kristin Sokol, MD, MPH, MS

CSU Guidelines: Similarities and Differences
Allen P. Kaplan, MD

CSU Management: A Focus on Emerging Therapies
Thomas B. Casale, MD, FACP, FAAAAI, FACAAI

Activity Chair

Allen P. Kaplan, MD
Professor of Medicine
The Medical University of South Carolina
Charleston, SC

Disclosures
Advisor: Abb-RISA, AstraZeneca, Genetech, Novartis, Roche, Sanofi
Consultant: Celldex, Novartis

Faculty

Thomas B. Casale, MD, FACP, FAAAAI, FACAAI
Chief Medical Advisor Food Allergy Research and Education (FARE)
Distinguished Chair, FARE Clinical Network
Professor of Medicine and Pediatrics
Director, Division of Allergy and Immunology Joy McCann Culverhouse Clinical Research Center
University of South Florida
Tampa, FL

Disclosures
Consultant: Genentech, GlaxoSmithKline, Novartis, Sanofi-Regeneron
Speaker Contracted by Ineligible Company: Genentech, GlaxoSmithKline, Sanofi-Regeneron
Independent Research Contractor: Genentech, Sanofi-Regeneron
Data Safety Monitoring Board: Novartis

Kristin Sokol, MD, MPH, MS
Allergist/Immunologist Physician
Schreiber Allergy
Rockville, MD

Disclosures
Speaker Contracted by Ineligible Company: Regeneron/Sanofi

Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Relationship information is accurate at the time of content development.

Vindico Medical Education Staff:
No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.25 hours credit for completing this program.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Unlabeled and Investigational Usage

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.

Disclaimer Statement

The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Notice

Faculty, topics, program schedule, and credit hours are subject to change. Recording of any manner is prohibited without written permission from Vindico Medical Education, Office of Medical Affairs and Compliance.

Contact Information for Questions About the Activity

CME Questions?
Contact us at cme@vindicoCME.com